Audeo Oncology (Audeo Oncology) EBIT per Share : $0.00 (TTM As of Sep. 2012)

View and export this data going back to . Start your Free Trial

What is Audeo Oncology EBIT per Share?

Audeo Oncology's EBIT per Share for the three months ended in Sep. 2012 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2012 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Audeo Oncology's EBIT per Share or its related term are showing as below:

AURX's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.7
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Audeo Oncology's EBIT for the three months ended in Sep. 2012 was $-4.81 Mil.

Audeo Oncology EBIT per Share Historical Data

The historical data trend for Audeo Oncology's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Audeo Oncology EBIT per Share Chart

Audeo Oncology Annual Data

Trend

Jun10

Jun11

Jun12

EBIT per Share

Audeo Oncology Quarterly Data
	Jun11	Mar12	Jun12	Sep12
EBIT per Share	-	-	-	-

Audeo Oncology EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Audeo Oncology's EBIT per Share for the fiscal year that ended in Jun. 2012 is calculated as

	EBIT per Share		(A: Jun. 2012 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-9.481	/	0
=	N/A

Audeo Oncology's EBIT per Share for the quarter that ended in Sep. 2012 is calculated as

	EBIT per Share		(Q: Sep. 2012 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-4.809	/	0
=	N/A

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

Audeo Oncology (DELISTED:AURX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Audeo Oncology EBIT per Share Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Audeo Oncology (Audeo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » EBIT per Share

Traded in Other Exchanges

N/A

Address

Website

http://www.audeooncology.com

Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.